Technical Analysis for MESO - Mesoblast Limited

Grade Last Price % Change Price Change
grade C 5.15 -0.39% -0.02
MESO closed down 0.39 percent on Monday, May 20, 2019, on 37 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MESO trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -0.39%
Down 3 Days in a Row Weakness -0.39%
Down 4 Days in a Row Weakness -0.39%
Down 5 Days in a Row Weakness -0.39%
Oversold Stochastic Weakness -0.39%
Fell Below 50 DMA Bearish -0.77%

Older signals for MESO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Biotechnology Health Life Sciences Pharmaceutical Industry Stem Cells Cardiovascular Diseases Therapeutic Products Technology Platforms Diabetic Nephropathy Back Pain Mesoblast Host Diseases Regenerative Biomedicine
Is MESO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.78
52 Week Low 3.35
Average Volume 61,725
200-Day Moving Average 5.4461
50-Day Moving Average 5.2672
20-Day Moving Average 5.4545
10-Day Moving Average 5.2997
Average True Range 0.1815
ADX 15.44
+DI 19.2129
-DI 25.8442
Chandelier Exit (Long, 3 ATRs ) 5.4555
Chandelier Exit (Short, 3 ATRs ) 5.6485
Upper Bollinger Band 5.8522
Lower Bollinger Band 5.0568
Percent B (%b) 0.12
BandWidth 14.582455
MACD Line -0.0388
MACD Signal Line 0.0234
MACD Histogram -0.0622
Fundamentals Value
Market Cap 437.47 Million
Num Shares 84.9 Million
EPS -0.97
Price-to-Earnings (P/E) Ratio -5.31
Price-to-Sales 193.69
Price-to-Book 0.90
PEG Ratio -0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.32
Resistance 3 (R3) 5.32 5.28 5.29
Resistance 2 (R2) 5.28 5.23 5.27 5.28
Resistance 1 (R1) 5.21 5.21 5.19 5.21 5.27
Pivot Point 5.17 5.17 5.16 5.16 5.17
Support 1 (S1) 5.10 5.12 5.08 5.10 5.03
Support 2 (S2) 5.06 5.10 5.05 5.02
Support 3 (S3) 4.99 5.06 5.01
Support 4 (S4) 4.99